Clinical trials: Scleroderma Systemic
Systemic Sclerosis, Fibromyalgia
Effects of Fibromyalgia Syndrome in Patients With Systemic Sclerosis
Systemic sclerosis [SSc]; is a multisystem disease characterized by immune activation, microvascular disease and fibroblast dysfunction, which is thought to occur as a result of complex and not fully understood interaction…
- Trial name
- NCT04411498
- Testing
- Fibromyalgia diagnosis in patients with SSc
- Where
- Turkey (Türkiye)
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Antalya Training and Research Hospital
Systemic Sclerosis
Implementation of a Biological Sample Collection in Systemic Sclerosis Patients
Systemic sclerosis (SSc) is the most severe of the systemic autoimmune diseases. It is characterized by skin and organ fibrosis (mainly interstitial lung disease, which affects 40-50% of patients), as well as severe vascular…
- Trial name
- SCLERO-BIOBANK (NCT04986514)
- Testing
- Bio-banking without genetic analysis
- Sponsor
- University Hospital, Lille
Systemic Sclerosis
RElevance of UltraSonography for Assessing Salivary Gland Involvement in Systemic Sclerosis (SSc)
As fibrosis of salivary glands is supposed to be the main mechanism involved in Systemic sclerosis (SSc)-associated sicca syndrome, Ultrasonography , biopsy and measuring gland elasticity (by ARFI (Acoustic Radiation Force…
- Trial name
- REUSSI-SSc (NCT04001556)
- Testing
- Minor Salivary gland Biopsy, ARFI, MSG US
- Where
- 3 sites in France
- Volunteers
- 75 people
- Sponsor
- Rennes University Hospital
Scleroderma
Taking Charge of Systemic Sclerosis
This Study is a collaborative project with partners (people with scleroderma and stakeholders) designed to refine an internet program for patients with scleroderma and to compare the internet program to an authoritative…
- Trial name
- TOSS (NCT02494401)
- Testing
- Internet-based self-management program, Scleroderma book
- Where
- United States
- Volunteers
- 267 people
- Sponsor
- University of Michigan
Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis)
A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy
This study will evaluate the safety and efficacy of the combination of rituximab and methotrexate to treat disabling fibrosing skin disorders.Rituximab will be administered at baseline and month 6.
- Trial name
- NCT00936546
- Testing
- Rituximab
- Where
- Belgium
- Volunteers
- 3 people
- Sponsor
- University Hospital, Ghent
Systemic Sclerosis
Professional and Personal Toxic Exposure in Systemic Sclerosis : Type, Intensity and Probability of Exposition
Systemic Sclerosis (SSc) is an inflammatory chronic disease that can lead to structural damage and handicap. The SSc physiopathology is multifactorial, including genetic and environmental risk factors.
- Trial name
- VISSEXPOSITION (NCT03543956)
- Testing
- Questionnaire
- Where
- France
- Volunteers
- 226 people
- Sponsor
- University Hospital, Bordeaux
Systemic Sclerosis
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis
The main purpose of the study is to see if GLPG1690 helps (together with the standard of care treatment) in the treatment of the skin and other areas affected by systemic sclerosis.
- Trial name
- NOVESA (NCT03798366)
- Testing
- GLPG1690
- Where
- 18 sites in United States, Belgium and 4 more
- Volunteers
- 33 people
- Sponsor
- Lakefront Biotherapeutics NV
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM)
Safety Study of CC312 in Autoimmune Disease Patients
This study is an open-label, multiple-dose escalation, Investigator-Initiated Trial (IIT) clinical trial designed to evaluate the safety and tolerability of CC312 in adult patients with relapsed and refractory autoimmune…
- Conditions
- Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA)
- Trial name
- NCT06888960
- Testing
- CC312
- Where
- China
- Volunteers
- 18 people
- Sponsor
- CytoCares Inc
Systemic Sclerosis, Pulmonary Arterial Hypertension
Extracellular Vesicle Dynamics Predicting Vascular Complications and Treatment Response in Systemic Sclerosis
Systemic sclerosis is a multisystem autoimmune disease characterized by vascular dysfunction, immune dysregulation, and progressive tissue fibrosis.
- Conditions
- Systemic Sclerosis, Pulmonary Arterial Hypertension, Digital Ulcers, Vascular Complications
- Trial name
- EVOLVE-SSc (NCT07717060)
- Testing
- Blood sampling, nailfold capillaroscopy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Scleroderma, Systemic
The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis
The aim of the study is to investigate whether bosentan added to usual care improves arterial stiffness after 3 months as measured as the pulse wave velocity (PWV) of the medium and large arteries corrected for blood pressure…
- Trial name
- CEASESTIFF (NCT02480335)
- Testing
- bosentan
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
Pregnancy, Systemic Lupus Erythematosus
Duke Autoimmunity in Pregnancy Registry
It is difficult to predict how a women with an autoimmune disease will do during pregnancy. Some women will improve, others will worsen. Some pregnancies progress normally and others become very complicated.
- Conditions
- Pregnancy, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis
- Trial name
- DAP Registry (NCT00513591)
- Where
- United States
- Volunteers
- 513 people, healthy volunteers welcome
- Sponsor
- Duke University
CREST Syndrome, Calcinosis Cutis
Localized Effects of PBM and Exogenous NO on CREST Patients Calcinosis Cutis & Raynaud Phenomenon
Background CREST is an acronym for the cardinal clinical features of the syndrome (Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia) and part of the heterogeneous group of sclerodermas.
- Conditions
- CREST Syndrome, Calcinosis Cutis, Raynaud Phenomenon
- Trial name
- NCT03972566
- Testing
- INOMAX
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- RoseLab Skin Optics Laboratory
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma
A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon
The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX0503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
- Conditions
- Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Other Autoimmune Disease
- Trial name
- NCT00577304
- Testing
- Nitroglycerin, Topical AmphiMatrix
- Where
- 17 sites in United States
- Volunteers
- 200 people
- Sponsor
- MediQuest Therapeutics
Digital Ulcers, Systemic Sclerosis
Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma
In an earlier clinical trial, RAPIDS-1, conducted in scleroderma patients with or without digital ulcers at baseline, bosentan significantly reduced the number of new digital ulcers versus placebo.
- Trial name
- RAPIDS-2 (NCT00077584)
- Testing
- Bosentan 62.5 mg, Bosentan 125 mg
- Volunteers
- 188 people
- Sponsor
- Actelion
Rheumatoid Arthritis, Ankylosing Spondylitis
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
TRANSREG will assess the safety and biological efficacy of low-dose IL2 as a Treg inducer in a set of 14 autoimmune and auto-inflammatory diseases, with the aim to select diseases in which further therapeutic development will be…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus, Psoriasis
- Trial name
- TRANSREG (NCT01988506)
- Testing
- Interleukin 2
- Where
- 11 sites in France
- Volunteers
- 81 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Sclerosis, Ulcer
Prevention and Treatment of Digital Ulcers in Systemic Sclerosis
Systemic sclerosis is an orphan, multiorgan disease affecting the connective tissue of the skin and several internal organs. Digital ulcers are frequent and have a major impact on the quality of life in patients with systemic…
- Trial name
- NCT01836263
- Where
- 11 sites in France, Germany and 4 more
- Volunteers
- 420 people
- Sponsor
- marco matucci cerinic
Systemic Sclerosis
Impact of Transcutaneous Auricular Vagus Nerve Stimulation on Digestive Symptoms in Systemic Sclerosis Systemic Sclerosis
The purpose of this study is to assess the effect of transcutaneous auricular vagus nerve stimulation (ta-VNS) on gastrointestinal symptoms and quality of life in systemic sclerosis (SSc) patients.
- Trial name
- AVADIS (NCT04971018)
- Testing
- Auricular vagus nerve stimulation
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Grenoble
Scleroderma
MRI for Screening and Monitoring Scleroderma ILD
The purpose of this study is to test MRI methods for evaluating patients with Scleroderma-associated interstitial lung disease.
- Trial name
- NCT05204355
- Testing
- MRI, Hyperpolarized Xe129, HRCT
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Kansas Medical Center
Systemic Sclerosis, Pulmonary Hypertension
Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension
Systemic sclerosis (SSc, also known as scleroderma) is a disease characterized by fibrosis of the skin and organs, inflammation, and an abnormal endothelial cell lining inside of vessels.
- Conditions
- Systemic Sclerosis, Pulmonary Hypertension, Scleroderma
- Trial name
- NCT02331225
- Testing
- No intervention given
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Scleroderma, Scleroderma Renal Crisis
Zibotentan Better Renal Scleroderma Outcome Study
Many patients with scleroderma have damage to their kidneys caused by the disease. There is limited evidence for treatments to prevent this damage or stop it progressing.
- Conditions
- Scleroderma, Scleroderma Renal Crisis, Chronic Kidney Disease
- Trial name
- ZEBRA (NCT02047708)
- Testing
- Zibotentan
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- University College, London